SY-5007

索特替尼

Report date: 2025/12/02 15:16:15
NME

Base Information

Drug NameSY-5007
Drug Alias NameSY-5007片首亦泽SY-5007SY5007
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor RET inhibitors
TargetsTyrosine-protein kinase receptor RET
Therapy Area/IndicationsMedullary thyroid cancer (MTC)Solid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesShouyao Holding (Beijing) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShouyao Holding (Beijing) Co Ltd
Inactive CompaniesN/A
Active IndicationsMedullary thyroid cancer (MTC)Solid tumoursCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A